• Preliminary results of studies sponsored by the manufacturer

  2023-05-09

  

  Preliminary results of studies sponsored by the manufacturer of ETC-1002 have also shown positive results for monotherapy in statin-intolerant patients and for the combined use of the ACL inhibitor plus other cholesterol-reducing agents. In patients with a documented history of intolerance to statin

• br Conclusions A large body of evidence

  2023-05-09

  

  Conclusions A large body of evidence indicates that oxidative stress is involved in the pathogenesis of NDDs. Hence, reducing oxidative stress or suppressing its downstream pathways may be beneficial for the treatment of these diseases, especially such chronic diseases as AD or glaucoma. Here we

• To investigate if WP increased CAT activity in cells C

  2023-05-08

  

  To investigate if WP increased CAT activity in cells, C2C12 muscle Gastrodin were treated with 0.1 to 0.4 mg/mL of WP (80.05% protein) for 24 h and then stressed with 0.75 mM H2O2 for 1 h (Xu et al., 2011). The CAT activity was significantly enhanced from 15.1 ± 0.7 to 23.7 ± 1.3 U/mg of total cell

• In summary present evidence suggests that antimicrobial ther

  2023-05-06

  

  In summary, present evidence suggests that antimicrobial therapy for intra-abdominal sepsis can be shortened in patients exhibiting a clinical response to treatment. Hence, clinicians should use the resolution of clinical signs of infection as a guide to determine when during the 4–7-day window anti

• Cancers that responded to immune checkpoint inhibitors

  2023-05-06

  

  Cancers that responded to immune checkpoint inhibitors were shown to present a type I interferon (IFN) signature in the TME 33, 34. Type I IFNs positively regulate the expression of tumor antigens and their crosspresentation by DCs to tumoricidal CTLs. Furthermore, CD8+ T cell develops full effector

• br LO and the secretase complex Supporting this concept

  2023-05-06

  

  5LO and the γ-secretase complex Supporting this concept, during a recent trial testing the γ-secretase inhibitor semagacestat (LY 450139), AD patients actually experienced a functional decline compared to patients who took a placebo in addition to several other significant adverse effects (Doody

• NLX a k a F or befiradol exhibits nanomolar affinity

  2023-05-06

  

  NLX-112 (a.k.a. F13640 or befiradol), exhibits nanomolar affinity at 5-HT1A receptors, and, in Z-Guggulsterone synthesis to the 5-HT1A receptor agonists listed above, it presents exceptional selectivity and high efficacy at these receptors (Colpaert et al., 2002, Newman-Tancredi et al., 2017). Addit

• Dual acting RAAS blockade and neprilysin inhibition has

  2023-05-04

  

  Dual-acting RAAS blockade and neprilysin inhibition has been evaluated in several clinical HF trials. In PARADIGM-HF [6,7], LCZ696 was superior to enalapril in reducing mortality and HF hospitalizations in symptomatic patients with HF with reduced EF. Augmented benefits on maladaptive cardiac remode

• In a working group exposed month old

  2023-04-28

  

  In 2008, a working group exposed 12-month-old transgenic mice (mutation for human amyloid precursor protein expression) and their non-transgenic littermates to isoflurane and halothane for 120min per day for five days. It was concluded that in the transgenic mouse there was overload of amyloid prote

• In addition we performed Western blot analysis of different

  2023-04-26

  

  In addition, we performed Western-blot analysis of different areas of mouse brain with Orlistat against mAck1 (Ureña et al., 2005). The data obtained showed a high rate of expression in neocortex, hippocampus, cerebellum, and brainstem (Fig. 4). More moderate levels of expression were seen in hypot

• On the basis of the above

  2023-04-26

  

  On the basis of the above information, we designed a new series of benzothiazole–piperazine derivatives (–) that have the aforementioned structural requirements (). Benzothiazole is an important ring system in the drug discovery studies of AD. There are several benzothiazole compounds that show pote

• am580 In this scenario the receptor tyrosine kinase

  2023-04-26

  

  In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; Pam580 in a c

• Introduction Cancer which is responsible

  2023-04-26

  

  Introduction Cancer, which is responsible for a million deaths each year, is universally feared, and approximately 50% of newly diagnosed cases can be cured [1]. The existing cancer treatments, including surgery, chemotherapy, radiotherapy or a combination of them, are quickly losing efficacy. The

• The Kelch like ECH associated protein Keap

  2023-04-26

  

  The Kelch-like ECH-associated protein 1 (Keap1)-Nrf2 signaling pathway functions as one of the key regulator of the cellular defense system against oxidative stress [26]. Nrf2 is a redox-sensitive transcription factor, that is sequestered in the cytoplam by binding to Keap1; however, under oxidative

• Imatinib is a well known anticancer drug used

  2023-04-26

  

  Imatinib is a well-known anticancer drug used in Chronic Myeloid Leukemia (CML) against the altered expression/activity of tyrosine kinase resulting from the fusion of BCR-ABL in leukemic blasts. It has been demonstrated that Imatinib can induce autophagy in BCR-ABL expressing SC75741 (K562 cell lin

15442 records 298/1030 page Previous Next First page 上5页 296297298299300 下5页 Last page